Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $1.5 million.

  • Cartesian Therapeutics' Interest & Investment Income fell 3983.68% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 3223.77%. This contributed to the annual value of $7.4 million for FY2024, which is 4879.13% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Interest & Investment Income stood at $1.5 million for Q3 2025, which was down 3983.68% from $1.7 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Interest & Investment Income high stood at $2.6 million for Q3 2024, and its period low was $9000.0 during Q4 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $1.2 million (2024), whereas its average is $1.0 million.
  • In the last 5 years, Cartesian Therapeutics' Interest & Investment Income tumbled by 9500.0% in 2021 and then skyrocketed by 1257777.78% in 2022.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Interest & Investment Income stood at $9000.0 in 2021, then surged by 12577.78% to $1.1 million in 2022, then fell by 17.62% to $940000.0 in 2023, then surged by 161.06% to $2.5 million in 2024, then crashed by 36.92% to $1.5 million in 2025.
  • Its Interest & Investment Income was $1.5 million in Q3 2025, compared to $1.7 million in Q2 2025 and $2.0 million in Q1 2025.